<DOC>
	<DOCNO>NCT00002751</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I/II trial study effectiveness monoclonal antibody therapy treat patient brain metastasis .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity maximum tolerate dose 131-iodine-labeled monoclonal antibody fragment Me1-14 F ( ab ' ) 2 administer intrathecally patient neoplasms metastatic leptomeninges . II . Identify objective therapeutic response treatment . OUTLINE : Radioimmunotherapy . Iodine-131-Labeled Monoclonal Antibody Fragment Me1-14 F ( ab ' ) 2 , 131I-Me1-14 F ( ab ' ) 2 . PROJECTED ACCRUAL : Three 6 patient treat dose study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm neoplasm recurrent subarachnoid space Biopsy recurrent lesion require original diagnosis make 2 year prior entry CSF cytology negative Radiographic evidence measurable lesion leptomeninges ( myelography , CT , MRI ) cytologic evidence malignancy CSF Any type neoplasm eligible provide tumor cell ( tissue CSF preparation ) bind significantly intact monoclonal antibody Me114 IgG2a Me114 F ( ab ' ) 2 Patency subarachnoid pathway demonstrate isotopic intraventricular flow PATIENT CHARACTERISTICS : Age : 3 Performance status : Karnofsky 50100 % Hematopoietic : Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : AST le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase less 1.5 time ULN Renal : Creatinine le 1.2 mg/dL Other : No allergy iodine Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior antineoplastic chemotherapy unless unequivocal evidence tumor progression No concurrent systemic chemotherapy Endocrine therapy : Corticosteroids allow low possible dose stable least 10 day prior entry Radiotherapy : At least 3 month since prior radiotherapy site measurable disease unless unequivocal evidence disease progression Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>leptomeningeal metastasis</keyword>
</DOC>